Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma

Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration f...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, So Young, Badrinath, Narayanasamy, Woo, Hyun Young, Heo, Jeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415860/
https://www.ncbi.nlm.nih.gov/pubmed/28512387
http://dx.doi.org/10.1155/2017/5198798
_version_ 1783233615823372288
author Yoo, So Young
Badrinath, Narayanasamy
Woo, Hyun Young
Heo, Jeong
author_facet Yoo, So Young
Badrinath, Narayanasamy
Woo, Hyun Young
Heo, Jeong
author_sort Yoo, So Young
collection PubMed
description Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months. Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules. This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs.
format Online
Article
Text
id pubmed-5415860
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-54158602017-05-16 Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma Yoo, So Young Badrinath, Narayanasamy Woo, Hyun Young Heo, Jeong Mediators Inflamm Review Article Hepatocellular carcinoma is highly refractory cancer which is resistant to conventional chemotherapy and radiotherapy, carrying a dismal prognosis. Although many anticancer drugs have been developed for treating HCC, sorafenib is the only effective treatment, but it only prolongs survival duration for about 3 months. Recently, oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by adopting immune modulatory molecules. This review discusses the current status of treating HCC and the effective strategy of oncolytic virus-based immunotherapy for the treatment of HCCs. Hindawi 2017 2017-04-20 /pmc/articles/PMC5415860/ /pubmed/28512387 http://dx.doi.org/10.1155/2017/5198798 Text en Copyright © 2017 So Young Yoo et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Yoo, So Young
Badrinath, Narayanasamy
Woo, Hyun Young
Heo, Jeong
Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
title Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
title_full Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
title_fullStr Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
title_full_unstemmed Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
title_short Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
title_sort oncolytic virus-based immunotherapies for hepatocellular carcinoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415860/
https://www.ncbi.nlm.nih.gov/pubmed/28512387
http://dx.doi.org/10.1155/2017/5198798
work_keys_str_mv AT yoosoyoung oncolyticvirusbasedimmunotherapiesforhepatocellularcarcinoma
AT badrinathnarayanasamy oncolyticvirusbasedimmunotherapiesforhepatocellularcarcinoma
AT woohyunyoung oncolyticvirusbasedimmunotherapiesforhepatocellularcarcinoma
AT heojeong oncolyticvirusbasedimmunotherapiesforhepatocellularcarcinoma

Ejemplares similares